Ruta Rao, MD

Experts discuss the evolving strategies in HER2-positive breast cancer treatment, focusing on maintenance therapies and patient-specific approaches.

Experts discuss the impact of biomarkers and treatment duration on decision-making for CDK4/6 inhibitors in breast cancer adjuvant therapy.

Discover effective strategies for managing toxicities in patients using CDK4/6 inhibitors, ensuring adherence and optimal treatment outcomes.

Experts discuss evolving strategies and unmet needs in HER2-positive breast cancer treatment, focusing on emerging therapies and clinical trial insights.

Clinicians explore barriers to adjuvant CDK4/6-inhibitor therapy, emphasizing education and streamlined communication to improve patient outcomes.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

Segment 1 establishes the current treatment landscape for HER2-positive metastatic breast cancer (mBC) and highlights key unmet clinical needs.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

CDK4/6 Inhibition in HR-Positive Breast Cancer: Evolving Standards in Early and Metastatic Care